Drug intelligence / Profile preview

Pru p 3

Development stage
Phase 3
Lead developer
Thermo Fisher Scientific
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Sublingual
01

Overview

Pru p 3 is a 9 kDa nonspecific lipid transfer protein (nsLTP) that serves as the primary allergen in peaches (*Prunus persica*). In Mediterranean populations, it is a major sensitizer responsible for severe food-allergic reactions, including anaphylaxis. As a therapeutic agent, Pru p 3 is utilized in allergen-specific immunotherapy (AIT), particularly via sublingual administration (SLIT), to induce clinical desensitization and long-term immune tolerance. The mechanism of action involves modulating the immune system toward a tolerogenic profile, characterized by epigenetic modifications such as DNA methylation changes in dendritic cells (DCs). These alterations regulate the expression of genes involved in T cell activation, antigen presentation, and inflammatory signaling, including HLA-DQA1, HLA-DQB1, FOXP1, and MTOR.

Other names
peach allergen Pru p 3nonspecific lipid transfer protein Pru p 3Prunus persica allergen 3Pru p 3-enriched extract
02

Targets

CLEC9A (C-type lectin domain family 9 member A)Dendritic cell receptors involved in Pru p 3 uptake and presentationPru p 3-specific B-cell receptors and antibodiesPru p 3-specific CD4+ T-cell receptorPru p 3-specific Immunoglobulin EIgE (Immunoglobulin E)

Beyond the preview

Go deeper on Pru p 3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pru p 3.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call